As the psychedelics industry is set to have another record-breaking year, we take a look at the milestones of 2021 and what we can expect in the coming year.
Continue reading
With investor interest in psychedelics heating up, Eleusis joins the relatively quiet SPAC market in a deal that gives the biotech $288 million to test a psilocybin-based treatment for depression. The proceeds will also bankroll an expansion of subsidiary Andala’s drug therapy clinics.
Continue reading
Seattle and Detroit approved this fall measures to protect consumers of “entheogenic” plants and fungi. These policies form part of a larger trend, which began […]
Continue reading
Rep. Brady Brammer acknowledges he’s not the type to run legislation on psychedelics.
Continue reading
Numinus Wellness recently announced important milestones in its clinical trial of MDMA-assisted therapy to treat individuals suffering from PTSD.
Continue reading
A wave of psychedelics legislation continues to sweep across the country.
Recently, lawmakers in Virginia and Kansas
Continue reading
Reilly: Lastly, do you think this will be a big year for 3D printing?
Continue reading
/PRNewswire/ — Nucleus, a South Florida startup focused on mental health data and technologies, today announced its launch. The company, which is wholly owned…
Continue reading
FORT LAUDERDALE, Fla., Jan. 19, 2022 /PRNewswire/ — Nucleus, a South Florida startup focused on mental health data and technologies, today announced its launch. The company, which is wholly owned
Continue reading
The year 2021 has not been kind to the psychedelics industry. The stock performances of the 60 publicly traded psychedelics companies on the Psychedelic Stock Index have been trending steadily downward since February 22, 2021, to their lowest point since the index began on June 1, 2020. The pandemic has definitely affected psychedelic business development. […]
Continue reading